Read this company snapshot
Daily valuation snapshot
Ocular Therapeutix, Inc.: source evidence dated 2026-10-09.
- Daily close (USD)
- $7.54
- Market capitalization (USD)
- $1,655,903,644.72
- Price / earnings (TTM)
- Not reported
- Price / book
- 3.18
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research OCUL in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research OCUL in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing OCUL with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $7.54 |
| Market capitalization (USD) | $1,655,903,644.72 |
| Price / earnings (TTM) | Not reported |
| Price / book | 3.18 |
No matching rows. Clear the filter to see all records.
Read OCUL's valuation metrics
Company size
Ocular Therapeutix, Inc.'s recorded market capitalization is $1,655,903,644.72. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
OCUL's recorded price-to-book ratio is 3.18. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Ocular Therapeutix, Inc. with Aurora
Use the snapshot above to ask a specific question about OCUL. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow OCUL's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.